{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:18:19Z","timestamp":1784704699979,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T00:00:00Z","timestamp":1383696000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s00259-013-2601-x","type":"journal-article","created":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T15:35:39Z","timestamp":1383665739000},"page":"505-510","source":"Crossref","is-referenced-by-count":80,"title":["Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate"],"prefix":"10.1007","volume":"41","author":[{"given":"Amir","family":"Sabet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich-Frank","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Reichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torjan","family":"Haslerud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojjat","family":"Ahmadzadehfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Biersack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nagarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,6]]},"reference":[{"issue":"2","key":"2601_CR1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.semnuclmed.2009.10.004","volume":"40","author":"DJ Kwekkeboom","year":"2010","unstructured":"Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010;40(2):78\u201388. doi: 10.1053\/j.semnuclmed.2009.10.004 .","journal-title":"Semin Nucl Med"},{"issue":"13","key":"2601_CR2","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26(13):2124\u201330. doi: 10.1200\/JCO.2007.15.2553 .","journal-title":"J Clin Oncol"},{"issue":"1","key":"2601_CR3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ecl.2010.12.003","volume":"40","author":"DJ Kwekkeboom","year":"2011","unstructured":"Kwekkeboom DJ, de Herder WW, Krenning EP. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40(1):173\u201385, ix. doi: 10.1016\/j.ecl.2010.12.003 .","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"2601_CR4","first-page":"1","volume":"44","author":"JR Buscombe","year":"2003","unstructured":"Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003;44(1):1\u20136.","journal-title":"J Nucl Med"},{"issue":"5","key":"2601_CR5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.7150\/thno.3739","volume":"2","author":"ES Delpassand","year":"2012","unstructured":"Delpassand ES, Samarghandi A, Mourtada JS, Zamanian S, Espenan GD, Sharif R, et al. Long-term survival, toxicity profile, and role of F-18 FDG PET\/CT scan in patients with progressive neuroendocrine tumors following peptide receptor radionuclide therapy with high activity In-111 pentetreotide. Theranostics 2012;2(5):472\u201380. doi: 10.7150\/thno.3739 .","journal-title":"Theranostics"},{"issue":"7","key":"2601_CR6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","volume":"12","author":"C Waldherr","year":"2001","unstructured":"Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12(7):941\u20135.","journal-title":"Ann Oncol"},{"issue":"5","key":"2601_CR7","first-page":"610","volume":"43","author":"C Waldherr","year":"2002","unstructured":"Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43(5):610\u20136.","journal-title":"J Nucl Med"},{"issue":"8","key":"2601_CR8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2967\/jnumed.111.090373","volume":"52","author":"S Ezziddin","year":"2011","unstructured":"Ezziddin S, Sabet A, Heinemann F, Yong-Hing CJ, Ahmadzadehfar H, Guhlke S, et al. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J Nucl Med 2011;52(8):1197\u2013203. doi: 10.2967\/jnumed.111.090373 .","journal-title":"J Nucl Med"},{"issue":"3","key":"2601_CR9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00259-010-1610-2","volume":"38","author":"S Ezziddin","year":"2011","unstructured":"Ezziddin S, Opitz M, Attassi M, Biermann K, Sabet A, Guhlke S, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2011;38(3):459\u201366. doi: 10.1007\/s00259-010-1610-2 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"2601_CR10","first-page":"1929","volume":"38","author":"BF Bernard","year":"1997","unstructured":"Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, et al. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997;38(12):1929\u201333.","journal-title":"J Nucl Med"},{"issue":"5","key":"2601_CR11","first-page":"617","volume":"43","author":"M Jong de","year":"2002","unstructured":"de Jong M, Krenning E. New advances in peptide receptor radionuclide therapy. J Nucl Med 2002;43(5):617\u201320.","journal-title":"J Nucl Med"},{"issue":"4","key":"2601_CR12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s002590100490","volume":"28","author":"G Paganelli","year":"2001","unstructured":"Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28(4):426\u201334.","journal-title":"Eur J Nucl Med"},{"issue":"11","key":"2601_CR13","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","volume":"26","author":"A Otte","year":"1999","unstructured":"Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26(11):1439\u201347.","journal-title":"Eur J Nucl Med"},{"issue":"10","key":"2601_CR14","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s002590100599","volume":"28","author":"M Cybulla","year":"2001","unstructured":"Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 2001;28(10):1552\u20134. doi: 10.1007\/s002590100599 .","journal-title":"Eur J Nucl Med"},{"issue":"4","key":"2601_CR15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdp372","volume":"21","author":"JB Cwikla","year":"2010","unstructured":"Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol 2010;21(4):787\u201394. doi: 10.1093\/annonc\/mdp372 .","journal-title":"Ann Oncol"},{"issue":"4","key":"2601_CR16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0272-6386(01)80135-9","volume":"37","author":"S Moll","year":"2001","unstructured":"Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001;37(4):847\u201351.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2601_CR17","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ndt\/16.5.1082","volume":"16","author":"MP Stoffel","year":"2001","unstructured":"Stoffel MP, Pollok M, Fries J, Baldamus CA. Radiation nephropathy after radiotherapy in metastatic medullary thyroid carcinoma. Nephrol Dial Transplant 2001;16(5):1082\u20133.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2601_CR18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/snuc.2002.31028","volume":"32","author":"TM Behr","year":"2002","unstructured":"Behr TM, Behe MP. Cholecystokinin-B\/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002;32(2):97\u2013109. doi: 10.1053\/snuc.2002.31028 .","journal-title":"Semin Nucl Med"},{"issue":"1","key":"2601_CR19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/cbr.2006.353","volume":"22","author":"F Forrer","year":"2007","unstructured":"Forrer F, Rolleman E, Bijster M, Melis M, Bernard B, Krenning EP, et al. From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging. Cancer Biother Radiopharm 2007;22(1):40\u20139. doi: 10.1089\/cbr.2006.353 .","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"2601_CR20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00259-006-0232-1","volume":"34","author":"EJ Rolleman","year":"2007","unstructured":"Rolleman EJ, Krenning EP, Bernard BF, de Visser M, Bijster M, Visser TJ, et al. Long-term toxicity of [(177)Lu-DOTA (0), Tyr (3)]octreotate in rats. Eur J Nucl Med Mol Imaging 2007;34(2):219\u201327. doi: 10.1007\/s00259-006-0232-1 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2601_CR21","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/j.1600-6143.2005.00861.x","volume":"5","author":"U P\u00f6ge","year":"2005","unstructured":"P\u00f6ge U, Gerhardt T, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 2005;5(6):1306\u201311. doi: 10.1111\/j.1600-6143.2005.00861.x .","journal-title":"Am J Transplant"},{"issue":"9","key":"2601_CR22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s002590100574","volume":"28","author":"DJ Kwekkeboom","year":"2001","unstructured":"Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001;28(9):1319\u201325.","journal-title":"Eur J Nucl Med"},{"issue":"8","key":"2601_CR23","first-page":"1310","volume":"46","author":"F Forrer","year":"2005","unstructured":"Forrer F, Uusij\u00e4rvi H, Storch D, Maecke HR, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 2005;46(8):1310\u20136.","journal-title":"J Nucl Med"},{"issue":"3","key":"2601_CR24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","volume":"30","author":"DJ Kwekkeboom","year":"2003","unstructured":"Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30(3):417\u201322. doi: 10.1007\/s00259-002-1050-8 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2601_CR25","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","volume":"35","author":"L Bodei","year":"2008","unstructured":"Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008;35(10):1847\u201356. doi: 10.1007\/s00259-008-0778-1 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2601_CR26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1667\/0033-7587(2003)159[0182:TNOADI]2.0.CO;2","volume":"159","author":"AA Flynn","year":"2003","unstructured":"Flynn AA, Pedley RB, Green AJ, Dearling JL, El-Emir E, Boxer GM, et al. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry. Radiat Res 2003;159(2):182\u20139.","journal-title":"Radiat Res"},{"issue":"6","key":"2601_CR27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00259-003-1142-0","volume":"30","author":"WA Breeman","year":"2003","unstructured":"Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30(6):917\u201320. doi: 10.1007\/s00259-003-1142-0 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2601_CR28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00259-002-1054-4","volume":"30","author":"WA Breeman","year":"2003","unstructured":"Breeman WA, van der Wansem K, Bernard BF, van Gameren A, Erion JL, Visser TJ, et al. The addition of DTPA to [177Lu-DOTA0, Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging 2003;30(2):312\u20135. doi: 10.1007\/s00259-002-1054-4 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"2601_CR29","first-page":"1243","volume":"26","author":"CD Russell","year":"1985","unstructured":"Russell CD, Bischoff PG, Kontzen FN, Rowell KL, Yester MV, Lloyd LK, et al. Measurement of glomerular filtration rate: single injection plasma clearance method without urine collection. J Nucl Med 1985;26(11):1243\u20137.","journal-title":"J Nucl Med"},{"issue":"12","key":"2601_CR30","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","volume":"38","author":"L Bodei","year":"2011","unstructured":"Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE: the IEO phase I\u2013II study. Eur J Nucl Med Mol Imaging 2011;38(12):2125\u201335. doi: 10.1007\/s00259-011-1902-1 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2601_CR31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/cbr.2012.1195","volume":"27","author":"SK Gupta","year":"2012","unstructured":"Gupta SK, Singla S, Bal C. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE. Cancer Biother Radiopharm 2012;27(9):593\u20139. doi: 10.1089\/cbr.2012.1195 .","journal-title":"Cancer Biother Radiopharm"},{"issue":"Suppl 1","key":"2601_CR32","first-page":"83S","volume":"46","author":"R Valkema","year":"2005","unstructured":"Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005;46 Suppl 1:83S\u201391S.","journal-title":"J Nucl Med"},{"issue":"12","key":"2601_CR33","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","volume":"23","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23(12):2754\u201362. doi: 10.1200\/JCO.2005.08.066 .","journal-title":"J Clin Oncol"},{"issue":"17","key":"2601_CR34","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","volume":"29","author":"A Imhof","year":"2011","unstructured":"Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29(17):2416\u201323. doi: 10.1200\/JCO.2010.33.7873 .","journal-title":"J Clin Oncol"},{"issue":"6","key":"2601_CR35","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.surg.2006.07.030","volume":"140","author":"A Frilling","year":"2006","unstructured":"Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, et al. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 2006;140(6):968\u201376. doi: 10.1016\/j.surg.2006.07.030 . discussion 76\u201377.","journal-title":"Surgery"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-013-2601-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-013-2601-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-013-2601-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:06:14Z","timestamp":1558699574000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-013-2601-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["2601"],"URL":"https:\/\/doi.org\/10.1007\/s00259-013-2601-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,6]]}}}